Clinical Impact of HIV Pretreatment Drug Resistance on First-Line Therapy

The emergence of HIV pretreatment drug resistance poses a critical challenge to global antiretroviral therapy programs. Pretreatment drug resistance refers to viral resistance mutations detected in treatment-naïve individuals or individuals re-initiating therapy. Furthermore, transmitted drug resistance undermines traditional non-nucleoside reverse transcriptase inhibitor regimens, leading to premature virologic failure. Consequently, clinicians encounter patients who fail to achieve viral suppression despite excellent treatment adherence. In response, global guidelines recommend integrase strand transfer inhibitors, particularly dolutegravir, as preferred first-line options due to their superior genetic barrier. However, ongoing transmission of resistant viral variants continues to threaten treatment durability in high-risk populations. Healthcare providers must recognize that baseline resistance profiles vary substantially across geographic regions and transmission groups. Additionally, next-generation sequencing technologies now allow laboratories to detect low-abundance drug-resistant variants that conventional Sanger sequencing frequently misses. Therefore, robust surveillance of pretreatment resistance remains essential to inform clinical guidelines and formulary selections. By identifying resistance trends early, clinicians can tailor initial antiretroviral regimens effectively, ensuring sustained viral suppression and reducing secondary transmission events.

Molecular Epidemiology and Viral Transmission Dynamics

Molecular epidemiological surveillance offers powerful insights into the hidden transmission networks driving localized HIV-1 epidemics. Specifically, researchers analyze the HIV-1 pol gene sequence to compute pairwise genetic distances between viral strains. Furthermore, individuals whose viral sequences exhibit high genetic similarity form discrete phylogenetic transmission clusters. In a cross-sectional molecular study of newly reported cases among men who have sex with men in Baotou, investigators sequenced the viral pol gene using next-generation sequencing. Consequently, the researchers constructed a high-resolution molecular transmission network using a precise genetic distance threshold of 1.30%. Among 176 successfully sequenced treatment-naïve individuals, nearly 30% clustered within 19 distinct transmission networks. Additionally, the study revealed circulating recombinant form CRF07_BC as the dominant viral subtype, accounting for over 56% of cases. Individuals infected with the CRF07_BC subtype demonstrated a nearly five-fold increased likelihood of cluster inclusion compared to other genotypes. Therefore, molecular surveillance demonstrates that viral subtype characteristics substantially influence transmission velocity and network expansion. Clinicians and epidemiologists can leverage these molecular clustering patterns to track active viral lineages and anticipate regional resistance dissemination.

Assortative Mixing and Sociodemographic Drivers of Infection

Phylogenetic networks do not form through random viral dissemination; rather, behavioral and sociodemographic factors govern cluster formation. Specifically, network analyses measure assortativity to determine whether individuals preferentially form partnerships with individuals sharing similar demographic traits. In the Baotou surveillance cohort, the transmission network demonstrated significant assortative mixing by age, marital status, and educational attainment. Furthermore, younger men who have sex with men exhibited dense clustering, reflecting closely connected social and sexual interaction networks. In addition, marital status significantly influenced network architecture, with never-married men demonstrating elevated cluster participation. However, married men within these networks also represent critical bridging populations who may inadvertently transmit HIV to female spouses. Consequently, secretive sexual relationships and intense societal stigma frequently delay testing and foster covert transmission chains. Therefore, clinical encounters must provide nonjudgmental sexual history screening and proactive HIV testing. Additionally, public health practitioners must design communication strategies that address demographic-specific preferences. By understanding assortative mixing dynamics, medical teams can deliver targeted prevention messaging that resonates directly with tightly knit, vulnerable peer groups.

Surveillance of Pretreatment Drug Resistance Mutations

Accurate monitoring of pretreatment drug resistance mutations guides empirical regimen design and therapeutic stewardship. In treatment-naïve cohorts, non-nucleoside reverse transcriptase inhibitor resistance mutations frequently represent the most prevalent class of resistance. Furthermore, mutations such as K103N, V106A, and Y181C confer cross-resistance across older non-nucleoside agents including efavirenz and nevirapine. In contrast, primary resistance mutations against integrase strand transfer inhibitors and protease inhibitors remain relatively uncommon in most surveillance cohorts. However, the presence of nucleoside reverse transcriptase inhibitor resistance, particularly M184V, can compromise backbone regimens relying on tenofovir and lamivudine. Consequently, molecular surveillance studies evaluate whether drug resistance mutations concentrate within specific transmission clusters. In many regional cohorts, clusters exhibit low overall pretreatment resistance, yet isolated clusters demonstrate concerning transmission of multiclass resistant strains. Therefore, routine baseline genotyping, when accessible, prevents the initiation of compromised regimens. Moreover, public health authorities must maintain centralized surveillance databases to detect newly emerging resistance clusters promptly. Through vigilant resistance surveillance, healthcare systems safeguard the therapeutic lifespan of modern antiretroviral regimens.

Translating Molecular Insights into Targeted Clinical Strategies

Integrating molecular surveillance data with clinical practice creates unprecedented opportunities to halt localized HIV transmission. First, public health teams can deploy rapid molecular cluster detection to identify expanding transmission hotspots in real time. Consequently, healthcare workers can focus aggressive contact tracing and partner notification services within active clusters. Furthermore, expanding pre-exposure prophylaxis access among tightly clustered social networks offers immediate protection to high-risk individuals. Additionally, same-day antiretroviral therapy initiation following diagnosis accelerates viral suppression, eliminating secondary transmission under the undetectable equals untransmittable principle. Clinicians must also provide culturally competent, stigma-free counseling to encourage routine viral load monitoring and long-term retention in care. Moreover, health systems should integrate community-based organizations into testing and linkage programs to reach hidden populations effectively. Thus, combining next-generation molecular diagnostics with compassionate clinical care bridges the gap between epidemiological data and frontline patient outcomes. Ultimately, targeted molecular epidemiology empowers clinicians and health authorities to dismantle transmission networks and accelerate progress toward ending the HIV epidemic.

What causes HIV pretreatment drug resistance in treatment-naive individuals?

Pretreatment drug resistance occurs when individuals acquire a drug-resistant viral strain from an infected partner or harbor resistance mutations from prior undisclosed antiretroviral exposures. Furthermore, transmitted drug resistance mutations persist in plasma despite the absence of active pharmacological pressure. Consequently, these resistant viral variants reduce the efficacy of standard first-line antiretroviral therapy. Therefore, baseline resistance surveillance remains critical for preserving regimen potency and preventing early therapeutic failure across diverse populations.

How does molecular transmission clustering assist HIV public health interventions?

Molecular transmission clustering uses viral genetic sequencing to identify active networks of ongoing transmission within specific demographic groups. In addition, constructing phylogenetic networks allows epidemiologists to detect rapidly expanding clusters and assess assortative mixing patterns. Consequently, public health authorities can deploy targeted resources, including enhanced testing, partner notification, and pre-exposure prophylaxis, directly to vulnerable populations. Thus, molecular surveillance transforms broad epidemiological data into precise, actionable public health interventions that effectively interrupt active transmission chains.

Why is dolutegravir preferred in areas with documented pretreatment resistance?

Dolutegravir demonstrates a remarkably high genetic barrier to resistance compared to non-nucleoside reverse transcriptase inhibitors such as efavirenz. Furthermore, clinical trials confirm that dolutegravir-based regimens achieve rapid viral suppression even in patients harboring baseline non-nucleoside or nucleoside resistance mutations. Consequently, global guidelines recommend dolutegravir as the preferred anchor agent for initial antiretroviral therapy. Therefore, adopting dolutegravir protects patients against treatment failure caused by circulating transmitted drug resistance and optimizes long-term therapeutic outcomes.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Healthcare professionals should exercise their independent clinical judgment. Refer to the latest local and national guidelines for clinical practice.

References

Li H et al. Molecular Transmission Clustering and Pretreatment Drug Resistance Among Men Infected With HIV-1 Who Have Sex With Men in Baotou, China: A Cross-Sectional Subgroup Analysis. JMIR Public Health Surveill. 2026 Nov 06. doi: 10.2196/82208. PMID: 42993954.

World Health Organization. HIV drug resistance report 2024. Geneva: World Health Organization; 2024.

National AIDS Control Organisation. National Guidelines for HIV Care and Treatment. New Delhi: Ministry of Health and Family Welfare, Government of India; 2021.